• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Put These Flyers Under Your Tree

These stocks may be speculative, but they sport solid sales-growth estimates -- and insiders are buying.  
By BRET JENSEN
Dec 24, 2012 | 09:30 AM EST
Stocks quotes in this article: AVEO, EPM

First of all, happy holidays to Real Money readers and my fellow contributors. I hope you have had a prosperous 2012 and enjoy many happy tidings in 2013.

As my regular readers know, I am mainly a value and contrarian investor. But, let's allow the holiday spirit work its magic today and depart from that a bit -- and go with a couple of speculative picks to put in one's stocking. Both of these stocks are selling at less than $10, and are what I call "leap of faith" names, since they operate in volatile industries and have scant analyst coverage. Even so, both have impressive projected revenue growth ahead, and insiders at both names have recently decided to make fresh purchases of the shares.

Aveo Pharmaceuticals (AVEO) is a company that's targeting cancer therapies using its Human Response Platform. Its lead product candidate is Tivozanib, an oral cancer drug in a Phase III clinical development that's meant to prevent tumor growth by inhibiting angiogenesis. The company also has a pipeline of monoclonal antibodies in development.

Here are four reasons Aveo is good speculative play at $6.50 a share:

1. Numerous insiders have purchased more than $900,000 worth of new shares over the last two weeks.

2. The company has a robust balance sheet, with more than 60% of its market capitalization in net cash on the books.

3. Analysts project the company will more than triple its revenue in 2013 -- to more than $65 million from an estimated $20 million this year. The company is still expected to lose money next year but, over the last two months, consensus earnings estimates for the coming year have improved markedly.

4. The six analysts who cover the stock have set a median price target of $14.50. The targets vary from $9 to $18 a share, all significantly above the current stock price.

Evolution Petroleum (EPM) develops and produces and oil and gas from its properties in Texas, Louisiana and Oklahoma.

Here are four reasons Evolution Petroleum is a good growth play at $8 a share:

1. There have been several insider purchases over the past few months.

2. Wall Street targets have risen more than 50% for fiscal 2013 (ends June 2013) in the last three months. For fiscal 2014, the company is projected to almost triple its earnings to $0.83 a share.

3. Revenue is also expected to nearly triple in fiscal 2014, and the company has quadrupled its operating cash flow in the last three years.

4. The mean price target is $11.75 for the four analysts that cover the stock. Price targets range from $11 to $14. The company has no debt, and has around 10% of its market capitalization in net cash.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jensen was long AVEO.

TAGS: Investing | U.S. Equity

More from Investing

Does the Fed Have a Credibility Problem?

Tom Graff
Mar 3, 2021 1:45 PM EST

The Fed is saying they won't hike, but with recent moves in eurodollar futures, the market is saying 'we don't believe you.'

Centene Charts Remain Weak and Vulnerable

Bruce Kamich
Mar 3, 2021 1:35 PM EST

Let's review the charts and indicators.

An Update on the Weakening Trade Desk Charts

Bruce Kamich
Mar 3, 2021 12:55 PM EST

We're in no rush to be a buyer.

Stopped Out on Johnson & Johnson but Willing to Buy it Lower

Bruce Kamich
Mar 3, 2021 12:20 PM EST

Stand aside for now.

Public Service Enterprise Group Stock: Wind at Its Back or Off the Grid?

Bruce Kamich
Mar 3, 2021 11:45 AM EST

Let's check out the charts of the N.J.-based utility.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:50 AM EST PAUL PRICE

    Michaels: Close to a Deal?

    It appears that a deal could be announced soon. ...
  • 08:34 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 3/3/2021

    SPX (Long-Term View) The 20 DMA @ 3889 with the ...
  • 06:05 PM EST PAUL PRICE

    Michael's (MIK) Up on Takeover Rumors

    The NYT says talks are underway regarding a buyout...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login